Taysha Gene Therapies, Inc. (TSHA)

5.77USD -3.19% (-0.19)

Over 6M: +27.4%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

4 5 6 7
Mar Apr May Jun Jul Aug

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.8
SBC / sales 331.3%
Accruals -3.7%
Asset turnover 0.012×
FCF margin -2417.0%
ROA -31.8%
ROCE -34.5%
ROE -38.6%
EBITDA margin —
Gross margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
ROIC —

2 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.8
EV/Sales 256.3×
EV/OE -9.3×
P/C 4.0×
P/B 4.7×
FCF yield -7.3%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

4.5
RPO / sales 1.0×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.8
Current ratio 22.5×
ND/EBITDA 0.29
Interest cover -3646.6×
Cash / Debt 9.2×
Debt / Eq 0.13×
Debt payback 0.0 yr
Quick ratio 17.8×
Cash runway 3.1 yr
F-score 4.5 pts
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.0
Sales/sh Y/Y -47.0%
Sales Q/Q -100.0%
Shares change +27.8%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.